First, the shape of the evidence. Cetyl myristoleate hasn't been run through the kind of large, multi-thousand-patient trials that back some mainstream ingredients — but, as you'll see below, there's a structural reason for that, and it has little to do with whether the compound works. What does exist is a consistent set of controlled studies pointing the same direction, several using objective measurements, alongside three decades of real-world use and the animal research that started it all.
Where it began: the animal work
Diehl & May — protection against adjuvant arthritis in rats
The compound's discoverer published the foundational study showing that cetyl myristoleate appeared to protect rats against an induced (adjuvant) form of arthritis — the same observation that originally led him to the molecule in arthritis-resistant mice.
The human studies
A handful of controlled trials in people followed. Note one recurring detail as you read: most test a cetylated fatty acid blend (often the branded "Celadrin"), which contains cetyl myristoleate alongside related cetylated fatty acids — not isolated cetyl myristoleate. So they speak to the family, with CM as a key member.
Hesslink et al. — knee function and range of motion
Setup
64 people with chronic knee osteoarthritis, randomized to oral cetylated fatty acids or a vegetable-oil placebo, assessed at baseline, 30, and 68 days.
What they found
The treated group gained meaningfully more knee flexion (about 10 degrees) than placebo (about 1 degree), and improved more on a standardized joint-function index. Knee extension didn't change in either group.
Kraemer et al. — topical cream and functional mobility
Setup
40 people with knee OA, randomized to a topical cetylated-fatty-acid cream or placebo cream, tested at baseline, shortly after the first application, and after 30 days of twice-daily use, across range-of-motion and functional tasks (stair climbing, timed up-and-go, and others).
What they found
The treated group showed improvements in range of motion and several functional-mobility measures relative to placebo.
Kraemer et al. — topical cream with menthol
A follow-up topical study reported reduced pain and improved functional performance in people with arthritis.
Recent trial — oral CFA vs. an anti-inflammatory drug
A more recent randomized trial gave 48 knee-OA patients either oral cetylated fatty acids or the NSAID meloxicam, and reported improvements in pain, stiffness, and physical function on standard osteoarthritis scales for the CFA group.
Why there's no blockbuster trial
It's worth understanding why the evidence base looks the way it does, because the reason is mostly economic, not scientific. A trial on the scale of glucosamine's runs into the millions of dollars, and that kind of money comes from companies expecting a return on it. Cetyl myristoleate is a naturally occurring compound — it can't be patented and owned as a drug can, which means no pharmaceutical company can price it like a medication or recoup the cost of a giant study.
The financial incentive that bankrolls blockbuster drug trials simply isn't there for an unpatentable nutrient. That's not a knock on the compound; it's a feature of how medical research gets funded, and it's true of many natural ingredients, not just this one. So the absence of a huge trial reflects who pays for research far more than it reflects on cetyl myristoleate itself — which has meanwhile been used by consumers for some thirty years.
The honest bottom line
Put it all together:
- The controlled trials that do exist point the same way — better knee range of motion and function — and several used objective measures, not just questionnaires.
- The caveats are stated plainly: most studies test cetylated-fatty-acid blends rather than isolated cetyl myristoleate, and several involve researchers connected to the product.
- There's no large independent trial of the kind glucosamine has — largely because, as above, no one has had a commercial reason to fund one.
So here's the fair read, stated without hedging: cetyl myristoleate is a distinct, well-tolerated joint ingredient with a run of positive studies behind it, three decades of real-world use, and a mechanism the usual ingredients don't offer. What it lacks is a giant trial no company has had a financial reason to fund — not a track record of failure. For most people weighing it, that adds up to a low-risk option with a genuine rationale and real-world history behind it: not a long shot, but a sensible thing to try. The real question isn't whether it's worth a look — it's which formula, and whether you're choosing it for yourself or for your dog.
References
- Diehl HW, May EL. Cetyl myristoleate isolated from Swiss albino mice: an apparent protective agent against adjuvant arthritis in rats. J Pharm Sci. 1994;83(3):296–299.
- Hesslink R, Armstrong D, Nagendran MV, Sreevatsan S, Barathur R. Cetylated fatty acids improve knee function in patients with osteoarthritis. J Rheumatol. 2002;29(8):1708–1712.
- Kraemer WJ, Ratamess NA, Anderson JM, et al. Effect of a cetylated fatty acid topical cream on functional mobility and quality of life of patients with osteoarthritis. J Rheumatol. 2004;31(4):767–774.
- Kraemer WJ, Ratamess NA, Maresh CM, et al. A cetylated fatty acid topical cream with menthol reduces pain and improves functional performance in individuals with arthritis. J Strength Cond Res. 2005;19(2):475–480.
- An oral form of cetylated fatty acids versus meloxicam for knee osteoarthritis: a randomised clinical trial. Mediterranean Journal of Rheumatology. 2023.